All In Biotech

Drug Trial Radar · NCT04640532

KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.

Last checked: Nov 19, 2026Latest source record: May 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 116 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

116

Planned (sponsor's estimate)

Start

Nov 17, 2020

Primary completion

May 11, 2022

Study completion Jul 24, 2025

Sponsor

Lead sponsor
Kartos Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Telios Pharma, Inc.
First posted
Nov 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.

Conditions

  • Myelofibrosis
  • Post-PV MF
  • Post-ET Myelofibrosis
  • Primary Myelofibrosis

Interventions

  • KRT-232Drug

    KRT-232, administered by mouth

  • TL-895Drug

    TL-895, administered by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b - The MTD/MAD and RP2D of TL-895 in combination with KRT-232 in patients with R/R MF (Cohort 1 and Cohort 2)Time frame: 56 Days
  2. Phase 2 - Spleen response rate for each cohortTime frame: 24 Weeks

Locations

37 sites in 10 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham School of Medicine, Division of Hematology and Oncology

    Birmingham, Alabama · Recruiting

  • The Oncology Institute of Hope

    Whittier, California · Recruiting

  • Lake City Cancer Center

    Lake City, Florida · Recruiting

  • Carle Cancer Center

    Urbana, Illinois · Recruiting

  • Columbia University Medical Center

    Fort Lee, New Jersey · Recruiting

  • Memorial Sloan Kettering Cancer Center (MSKCC)

    New York, New York · Recruiting

  • LKH Hochsteiermark

    Leoben, Austria · Recruiting

  • Meduni Wien, Univ. Klinik für Innere Medizin I

    Vienna, Austria · Recruiting

  • University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski, Pleven

    Pleven, Bulgaria · Recruiting

  • University Multiprofile Hospital for Active Treatment Dr. Georgi Plovdiv

    Plovdiv, Bulgaria · Recruiting

  • Hematology Clinic Specialized Hospital for Active Treatment of Hematological Diseases, Sofia

    Sofia, Bulgaria · Recruiting

  • Chu Amiens Picardie Site Sud

    Amiens, France · Recruiting

  • CHU de Limoges Service Hématologie Clinique et Thérapie Cellulaire

    Limoges, France · Recruiting

  • CHU Nantes - Hôtel Dieu

    Nantes, France · Recruiting

  • CHU de Nice Hospital

    Nice, France · Recruiting

  • Hôpital Saint Louis

    Paris, France · Recruiting

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, France · Recruiting

  • University Hospital Halle (Saale), Department of Internal Medicine IV - Hematology and Oncology

    Halle, Germany · Recruiting

  • University Hospital Marburg, Department of Hematology, Oncology and Immunology

    Marburg, Germany · Recruiting

  • Moritz Kaposi General Hospital, Department of Hematology

    Kaposvár, Hungary · Recruiting

  • Szabolcs-Szatmar-Bereg County Hospitals and University Teaching Hospital, Department of Hematology

    Nyíregyháza, Hungary · Recruiting

  • Medical Center of the University of Pecs, 1st Department of Internal Medicine, Division of Hematology

    Pécs, Hungary · Recruiting

  • Fejer County St. Gyorgy University Teaching Hospital, Department of Internal Medicine III, Hematology

    Székesfehérvár, Hungary · Recruiting

  • Polyclinic S. Orsola-Malpighi

    Bologna, Italy · Recruiting

  • ASST Spedali Civili di Brescia

    Brescia, Italy · Recruiting

  • Careggi University Hospital

    Florence, Italy · Recruiting

  • Hospital Casa Sollievo della Sofferenza, Department of Oncology and Hematology, Division of Hematology

    Foggia, Italy · Recruiting

  • Hospital of Ravenna, Operative Unit of Hematology

    Ravenna, Italy · Recruiting

  • Jan Biziel University Hospital #2 in Bydgoszcz, Department of Hematology

    Bydgoszcz, Poland · Recruiting

  • Pratia Onkologia Katowice

    Katowice, Poland · Recruiting

  • Frederic Chopin Provincial Teaching Hospital No. 1 in Rzeszow, Department of Hematology

    Rzeszów, Poland · Recruiting

  • Slupsk Provincial Specialist Hospital n.a. Janusz Korczak, Department of Hematology

    Słupsk, Poland · Recruiting

  • Nasz Lekarz Medical Outpatient Clinics Slawomir Jeka

    Torun, Poland · Recruiting

  • Clinical Center of Serbia

    Belgrade, Serbia · Recruiting

  • Clinical Center of Vojvodina

    Novi Sad, Serbia · Recruiting

  • Hematologia Clínica

    Barcelona, Spain · Recruiting

  • University Clinical Hospital of Salamanca, Department of Hematology

    Salamanca, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.